Tuesday, July 04, 2017 8:34:37 PM
Rexista Should Be The Best-in-Class Oxycodone and Grasp Decent Market Share: We believe regulations for opioids are likely going to be more strictly enforced based on recent FDA events (the FDA asked Endo to remove Opana ER from the market and issued a complete response letter (CRL) to Egalet regarding the prior approval supplement (PAS) of Oxaydo, as well, a public FDA meeting on July 10th and 11th is also to be held regarding
opioid drugs with abuse-deterrent properties). We believe IPCI’s Rexista has the most disruptive technologies to prevent opioid abuse in the category of oxycodone to date and based on that it should obtain a decent share in the opioid market once launched. We expect Rexista to be U.S. launched in 2018 after IPCI resolves the patent dispute with Purdue. IPCI
needs to find a strong U.S. marketing partner to showcase this product.
IMPACT – Maintaining our SPECULATIVE BUY rating and US$6 TP
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM